Table S3 from SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
Abstract
Table S3 shows the anti-tumor activity in cell lines of multiple cancer types.
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Protein Degradation and Inhibitors
Cancer Immunotherapy and Biomarkers
Publication details
- Publication date
- 4 February 2026